ISRCTN17405388 https://doi.org/10.1186/ISRCTN17405388

Phase I trial BDD code: BDD22320

Submission date 24/07/2025	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [X] Record updated in last year
Registration date 24/07/2025	**Overall study status** Deferred	
Last Edited 24/07/2025	**Condition category** Other	

Plain English summary of protocol
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

Contact information

Type(s)
Public, Scientific, Principal Investigator

Contact name
Dr Lyn Corry

ORCID ID
https://orcid.org/0009-0008-4224-4667

Contact details
BDD Pharma Ltd
Within Glasgow Royal Infirmary
84 Castle Street
Glasgow
United Kingdom
G4 0SF
0141 552 8791
Lyn.Corry@bddpharma.com

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number
1009022

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
MOS118-101

Study information

Scientific Title
Phase I trial BDD code: BDD22320

Study objectives
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 04/03/2024, London - Brent Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)2071048128; brent.rec@hra.nhs.uk), ref: 24/LO/0003

Study design
Pharmacoscintigraphic open-label crossover study

Primary study design
Interventional

Secondary study design
Non randomised study

Study setting(s)
Other

Study type(s)
Other

Participant information sheet

Health condition(s) or problem(s) studied
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

Interventions
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

Intervention Type
Drug

Pharmaceutical study type(s)
Pharmacokinetic, Scintigraphy

Phase
Phase I

Drug/device/biological/vaccine name(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

Primary outcome measure
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

Secondary outcome measures
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

Overall study start date
01/09/2023

Completion date
18/08/2025

Eligibility

Key inclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

Participant type(s)
Healthy volunteer

Age group
Adult

Lower age limit
18 Years

Upper age limit
65 Years

Sex

Both

Target number of participants
8

Key exclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

Date of first enrolment
09/06/2025

Date of final enrolment
23/06/2025

Locations

Countries of recruitment
Scotland

United Kingdom

Study participating centre
BDD Pharma Ltd
Glasgow Royal Infirmary
84 Castle Street
Glasgow
United Kingdom
G4 0SF

Sponsor information

Organisation
Mosanna Therapeutics

Sponsor details
c/o Walder Wyss AG
Aeschenvorstadt 48
Basel
Switzerland
4051
+1 (650) 381-9916
info@mosanna.com

Sponsor type
Industry

Website
https://mosanna.com/

Funder(s)

Funder type
Industry

Funder Name
Mosanna Therapeutics

Results and Publications

Publication and dissemination plan
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial because of the high commercial sensitivity of this phase I study. Results will be posted on or after the date of publication of full trial details.

Intention to publish date
18/08/2026

Individual participant data (IPD) sharing plan
The datasets generated and/or analysed during the study are not expected to be made available because of the high commercial sensitivity of this phase I study and the negligible benefit to the public of phase I information.

IPD sharing plan summary
Not expected to be made available